Jänicke U A, Coper H
Drug Alcohol Depend. 1984 Jan;13(1):43-54. doi: 10.1016/0376-8716(84)90031-0.
Investigations were performed to determine whether the pharmacodynamic effect of barbital, the development of tolerance to or the physical dependence on the hypnotic are responsible for drug-taking behavior. Three groups of male rats, untreated, tolerant to and physically-dependent on barbital, were given free choice between 0.5% barbital solution and tap water. Drug-taking behavior was estimated according to specified criteria. Initially naive rats rejected an unsweetened barbital solution. Tolerant rats also refused the hypnotic, even after they had experienced abstinence symptoms only once. However, tolerant rats that repeatedly underwent withdrawal after an intake of more than 400 mg/kg/day of barbital did show drug taking behavior. Therefore, several experiences with pronounced abstinence symptoms seem to be necessary for initiating and sustaining barbital drug taking behavior in rats.
进行了多项研究,以确定巴比妥的药效、对该催眠药耐受性的发展或身体依赖性是否与药物摄取行为有关。三组雄性大鼠,分别为未处理组、对巴比妥耐受组和对巴比妥产生身体依赖组,让它们在0.5%巴比妥溶液和自来水之间自由选择。根据特定标准评估药物摄取行为。最初未经处理的大鼠拒绝未加糖的巴比妥溶液。耐受大鼠也拒绝该催眠药,即使它们仅经历过一次戒断症状。然而,在摄入超过400mg/kg/天的巴比妥后反复经历戒断的耐受大鼠确实表现出药物摄取行为。因此,似乎需要多次经历明显的戒断症状才能引发并维持大鼠的巴比妥药物摄取行为。